Soligenix Inc. (SNGX)

US · Healthcare · Biotechnology

$0.38+4.19%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-2.0M

EPS

$-0.12

EPS estimate

$-0.22

EPS came in at -0.12 against a street estimate of -0.22 — a beat of 45.5%.

Market cap

$7.9M

Forward P/E

12.3

P/B

1.20

Book value

$0.31

EPS (TTM)

$-0.72

52-week high

$2.86

52-week low

$0.28

50-day MA

$0.38

200-day MA

$0.87

Beta

1.92

Analysts rate Soligenix Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1.38.

Insiders

4.59%

Institutions

6.72%

Fund	Stake
Citadel Advisors Llc	0.96%
Geode Capital Management, LLC	0.55%
Vanguard Capital Management, LLC	0.27%
Vanguard Fiduciary Trust Co	0.25%
XTX Topco Ltd	0.10%
Morgan Stanley - Brokerage Accounts	0.02%
Mercer Global Advisors Inc.	0.01%
UBS Group AG	0.01%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Soligenix Inc. — free to start.

Data updated 2026-09-18.